Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)

NCT02132169 is registered in ClinicalTrials.gov with Aciex Therapeutics, Inc. as lead sponsor.

NCT NCT02132169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02132169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)
Lead sponsor
Aciex Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2014
Completion date
October 31, 2014
Enrollment
512 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic disease (including allergic conjunctivitis)